Personalized Geriatric Pharmacotherapy: Pharmacogenomics, Polypharmacy, and Age-Related Pharmacokinetic and Pharmacodynamic Changes
- 1Russian Clinical Research Center of Gerontology, Pirogov Russian National Research Medical University of the Ministry of Healthcare of the Russian Federation, 129226 Moscow, Russia
Abstract
Aging induces profound physiological changes that alter drug disposition and response, narrowing therapeutic windows and increasing susceptibility to adverse drug reactions (ADRs). This review synthesizes current evidence on age-related pharmacokinetic and pharmacodynamic changes, with a focus on pharmacogenomic determinants of drug response in older adults. Progressive decline in renal function and hepatic metabolic capacity and alterations in body composition collectively necessitate age-appropriate dose adjustments. Polypharmacy, prevalent in community-dwelling and hospitalized older adults, compounds these challenges through drug–drug and drug–drug–gene interactions. Pharmacogenomic testing—particularly for CYP2D6, CYP2C19, CYP2C9, and SLCO1B1—offers a promising strategy with which to personalize therapy, while deprescribing frameworks provide practical approaches to mitigating medication-related risks. This review provides a comprehensive framework for understanding the mechanistic basis of altered drug response in older adults and proposes actionable strategies for optimizing pharmacotherapy in this vulnerable population. Throughout, pharmacogenomic claims are graded across four levels: biological plausibility, measured pharmacokinetic effect, pharmacogenetic actionability, and demonstrated clinical utility. Furthermore, selected gene–drug examples are explicitly identified as either geriatric-specific evidence or extrapolations from general adult pharmacogenomics, clarifying which findings are truly modified by the aging process.
Related
- Clinical pharmacokinetic-pharmacodynamic relationships between drug exposure and the QT/QTc interval: Protocol for a systematic review and quantitative synthesis
- Cell-resolved pharmacodynamic profiling reveals tissue- and cell-population-specific activity of antisense oligonucleotide chemical conjugates in vivo
- Monitoring pharmacodynamic and molecular drug targets in liquid biopsy: Exploratory study in liver cancer with modelling of EGFR Receptor engagement
- Gut microbiota–cancer crosstalk: emerging molecular targets for personalized cancer treatment- a comprehensive review
- Feasibility and efficacy of personalized cardiorespiratory and strength exercise in Duchenne muscular dystrophy: a pilot study
BibTeX
@article{buianova2026personalized,
title = {{Personalized Geriatric Pharmacotherapy: Pharmacogenomics, Polypharmacy, and Age-Related Pharmacokinetic and Pharmacodynamic Changes}},
author = {Anastasiia A. Buianova and Iaroslav V. Mironenko and Mikhail S. Arbatskiy and Alexey V. Churov},
journal = {International Journal of Molecular Sciences},
year = {2026},
month = nov,
doi = {10.3390/ijms27219948},
url = {https://www.mdpi.com/1422-0067/27/21/9948},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Personalized Geriatric Pharmacotherapy: Pharmacogenomics, Polypharmacy, and Age-Related Pharmacokinetic and Pharmacodynamic Changes
AU - Anastasiia A. Buianova
AU - Iaroslav V. Mironenko
AU - Mikhail S. Arbatskiy
AU - Alexey V. Churov
PY - 2026
DA - 2026/11/06
JO - International Journal of Molecular Sciences
DO - 10.3390/ijms27219948
UR - https://www.mdpi.com/1422-0067/27/21/9948
AB - Aging induces profound physiological changes that alter drug disposition and response, narrowing therapeutic windows and increasing susceptibility to adverse drug reactions (ADRs). This review synthesizes current evidence on age-related pharmacokinetic and pharmacodynamic changes, with a focus on pharmacogenomic determinants of drug response in older adults. Progressive decline in renal function and hepatic metabolic capacity and alterations in body composition collectively necessitate age-appropriate dose adjustments. Polypharmacy, prevalent in community-dwelling and hospitalized older adults, compounds these challenges through drug–drug and drug–drug–gene interactions. Pharmacogenomic testing—particularly for CYP2D6, CYP2C19, CYP2C9, and SLCO1B1—offers a promising strategy with which to personalize therapy, while deprescribing frameworks provide practical approaches to mitigating medication-related risks. This review provides a comprehensive framework for understanding the mechanistic basis of altered drug response in older adults and proposes actionable strategies for optimizing pharmacotherapy in this vulnerable population. Throughout, pharmacogenomic claims are graded across four levels: biological plausibility, measured pharmacokinetic effect, pharmacogenetic actionability, and demonstrated clinical utility. Furthermore, selected gene–drug examples are explicitly identified as either geriatric-specific evidence or extrapolations from general adult pharmacogenomics, clarifying which findings are truly modified by the aging process.
SN - 1422-0067
ER -